Brief: Xspray Q3 Adjusted EPS SEK -1.59
08/11/2023 07:02
Nov 8 (Reuters) - Xspray Q3 adjusted free cash flow SEK -68.611 million. * Q3 pretax profit SEK -38.942 million * Q3 adjusted EPS SEK -1.59 * Q3 revenue SEK 0
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003